| 764538 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
328 Batf3 dendritic cells and 4–1BB/4–1BB ligand axis are required at the effector phase within the tumor microenvironment for anti-PD-L1 efficacy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.328 |
Ziblat Andrea, Horton Brendan, Higgs Emily, Hatogai Ken, Gajewski Thomas |
| 764537 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
323 Immunogenic syngeneic model MC38-OVA for the preclinical evaluation of immune evasion and checkpoint blockade |
2021-11-01 |
10.1136/jitc-2021-sitc2021.323 |
Wang Jessie, Lian Kaixia, Zheng Jia, Nie Chenpan, An Annie, Li Henry |
| 764536 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
322 Melanoma-intrinsic hypoxia-inducible factor-1α results in diminished T cell accumulation within the tumor microenvironment |
2021-11-01 |
10.1136/jitc-2021-sitc2021.322 |
Higgs Emily, Gajewski Thomas, Trujillo Jonathan |
| 764535 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
321 PD-L1 checkpoint blockade eradicates residual leukemia in a mouse model of acute lymphoblastic leukemia by countering exhaustion of cytotoxic and effector CD4+ T-cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.321 |
Tracy Sean, Venkatesh Hrishi, Heltemes-Harris Lynn, Hubbard Gregory, Hekim Can, Farrar Michael |
| 764534 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
320 Tumor cell-intrinsic signaling mediates T cell exclusion and promotes resistance to checkpoint blockade therapy in non-small cell lung cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.320 |
Torres-Mejia Elen, Nguyen Kim, Duong Ellen, Spranger Stefani |
| 764533 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
319 The tumor-intrinsic NLRP3 inflammasome establishes a pulmonary metastatic niche via type II epithelial HSP70/TLR4 signaling and facilitates disease hyperprogression in response to immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.319 |
Theivanthiran Balamayooran, Liu Fang, DeVito Nicholas, Plebanek Michael, Hanks Brent |
| 764532 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
318 Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance |
2021-11-01 |
10.1136/jitc-2021-sitc2021.318 |
Taylor Brandie, Balko Justin, Sanders Melinda, Gonzalez-Ericsson Paula, Sanchez Violeta |
| 764531 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
314 NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.314 |
Salome Berengere, Sfakianos John, Charap Andrew, Farkas Adam, Geanon Daniel, Kelly Geoffrey, Real Ronaldo de, Lee Brian, Beaumont Kristin, Shroff Sanjana, Wang Ying-Chih, Wang Yuan-Shuo, Wang Li, Sebra Robert, Kamphorst Alice, Malmberg Karl-Johan, Marcenaro Emanuela, Romero Pedro, Brody Rachel, Yuki Yuko, Martin Maureen, Carrington Mary, Mehrazin Reza, Wiklund Peter, Zhu Jun, Galsky Matthew, Bhardwaj Nina, Horowitz Amir |
| 764530 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
304 Antagonistic antibodies targeting LAIR1 enhance T lymphocyte activation and promote inflammatory phenotypes in myeloid cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.304 |
Huang Tao, Bonnans Caroline, Costa Maria Jose, Tabrizi Azita, Ma Jing-Tyan, Xie Jingjing, Chen Heyu, Hong Kyu, McCutcheon Krista, Stafford Ryan, Tian Hongyu, Zhang Cheng Cheng, Gui Xun, Zhang Ningyan, An Zhiqiang, Charlene Liao X, Song An |
| 764529 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
817 Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.817 |
Reid Pankti, Liew David, Akruwala Rajshi, Bass Anne, Chan Karmela |
